Corcept Therapeutics Inc (CORT)
23.78
+0.45
(+1.93%)
USD |
NASDAQ |
May 01, 16:00
27.50
+3.72
(+15.64%)
After-Hours: 20:00
Corcept Therapeutics Cash from Financing (Quarterly): 0.766M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.766M |
| September 30, 2023 | -3.916M |
| June 30, 2023 | -145.75M |
| March 31, 2023 | 0.181M |
| December 31, 2022 | -0.061M |
| September 30, 2022 | -13.96M |
| June 30, 2022 | -2.756M |
| March 31, 2022 | -0.506M |
| December 31, 2021 | -206.97M |
| September 30, 2021 | -23.64M |
| June 30, 2021 | -26.03M |
| March 31, 2021 | -45.95M |
| December 31, 2020 | -0.661M |
| September 30, 2020 | 5.866M |
| June 30, 2020 | 6.804M |
| March 31, 2020 | 0.205M |
| December 31, 2019 | -0.144M |
| September 30, 2019 | 2.696M |
| June 30, 2019 | -15.91M |
| March 31, 2019 | -15.29M |
| December 31, 2018 | -12.03M |
| September 30, 2018 | -8.27M |
| June 30, 2018 | 4.044M |
| March 31, 2018 | 1.922M |
| December 31, 2017 | 2.567M |
| Date | Value |
|---|---|
| September 30, 2017 | -1.841M |
| June 30, 2017 | -4.971M |
| March 31, 2017 | -3.708M |
| December 31, 2016 | -0.823M |
| September 30, 2016 | -2.769M |
| June 30, 2016 | -0.538M |
| March 31, 2016 | -2.966M |
| December 31, 2015 | -0.195M |
| September 30, 2015 | -1.481M |
| June 30, 2015 | -0.766M |
| March 31, 2015 | 15.52M |
| December 31, 2014 | -1.129M |
| September 30, 2014 | -1.249M |
| June 30, 2014 | -0.612M |
| March 31, 2014 | -0.089M |
| December 31, 2013 | -0.592M |
| September 30, 2013 | -0.378M |
| June 30, 2013 | 0.00 |
| March 31, 2013 | 0.00 |
| December 31, 2012 | 0.204M |
| September 30, 2012 | 76.01M |
| June 30, 2012 | 0.198M |
| March 31, 2012 | 13.16M |
| December 31, 2011 | 0.045M |
| September 30, 2011 | 0.283M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-206.97M
Minimum
Dec 2021
6.804M
Maximum
Jun 2020
-24.72M
Average
-0.661M
Median
Dec 2020
Cash from Financing (Quarterly) Benchmarks
| Ultragenyx Pharmaceutical Inc | 330.61M |
| Alnylam Pharmaceuticals Inc | 39.23M |
| Catalyst Pharmaceuticals Inc | -0.665M |
| United Therapeutics Corp | -92.80M |
| XOMA Corp | 124.49M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 5.887M |
| Cash from Investing (Quarterly) | 17.10M |
| Free Cash Flow | 126.90M |
| Free Cash Flow Per Share (Quarterly) | 0.0531 |
| Free Cash Flow to Equity (Quarterly) | 5.887M |
| Free Cash Flow to Firm (Quarterly) | 5.887M |
| Free Cash Flow Yield | 4.78% |